Skip to mainSkip to footer

Carmignac Portfolio Grandchildren: Letter from the Fund Managers - Q3 2026

Author(s)
Mark DENHAM,Obe EJIKEME
Published on
21 October 2026
Read time
4 minute(s) read
+1.70%
Performance of the A EUR Share class1 in Q3 2026.
+2.55%
Performance of its reference indicator2 in Q3 2026.
+9.36%
Annualized performance of the A EUR Share class since launch (31/05/2019) vs +14.04% for its reference indicator.

During the third quarter of 2026, Carmignac Portfolio Grandchildren (A EUR Acc share class) posted a positive return of +1.70%, below its reference indicator, which rose +2.55%.

Market environment during the period

Global developed equity markets advanced during the third quarter of 2026, but the headline gain concealed unusually wide dispersion. US large-cap technology remained an important source of market support, with enthusiasm around artificial intelligence (AI) increasingly focused on companies able to demonstrate tangible monetisation and sustained cloud and data-centre demand. At the same time, the rally was far from uniform: higher energy prices, rising bond yields and renewed inflation concerns placed pressure on many long-duration and consumer-sensitive businesses.

The macroeconomic backdrop became less benign as the quarter progressed. The conflict in the Middle East pushed energy prices sharply higher and revived inflation concerns. In September, both the Federal Reserve (Fed) and the European Central Bank (ECB) raised policy rates by 25 basis points, while long-term sovereign yields moved higher across developed markets. Despite this tightening in financial conditions, economic activity remained relatively resilient, particularly in the United States, allowing investors to continue rewarding companies delivering strong earnings growth while penalising businesses where expectations or valuations appeared vulnerable.

Sector leadership therefore remained fragmented. Technology and selected Financials performed strongly, while Energy benefited materially from higher commodity prices. Healthcare outcomes were mixed but stock-specific opportunities were significant. Consumer Discretionary and several quality defensive franchises came under pressure as higher rates and changing market narratives weighed on valuations. For a concentrated global portfolio focused on sustainable, high-return businesses, the quarter was characterised less by a single macro factor than by substantial dispersion between individual companies.

How did we fare in this context?

Against this backdrop, the portfolio generated a positive absolute return but lagged its reference indicator. At the sector level, the largest positive absolute contributions came from Information Technology, Financials and Healthcare. The portfolio’s lower equity exposure and absence of Energy were headwinds to relative performance, while stock selection remained positive overall.

Information Technology was the largest absolute contributor. Microsoft was the strongest individual contributor to the Fund, rising almost 39% during the quarter as strong Azure performance and growing confidence in the monetisation of AI supported the shares. Nvidia also contributed close to one percentage point, gaining around 15% as demand for AI infrastructure remained robust. SAP and ServiceNow were additional positive contributors. We nevertheless maintained valuation discipline: Nvidia was trimmed after strength, while exposure to Arista was reduced and ultimately exited. Conversely, volatility in ASML and Broadcom created periods of weakness, with both detracting from performance despite our continued conviction in the long-term semiconductor and AI infrastructure opportunity.

Healthcare was another important positive contributor in absolute terms, although returns within the sector were highly dispersed. ThermoFisher was a standout performer, rising more than 35%, while Genmab and Regeneron also delivered strong gains. Genmab was actively managed during the period: we added on weakness and subsequently trimmed after a strong run. Against these gains, AstraZeneca, Galderma, Align Technology and EssilorLuxottica detracted. We used several of these setbacks to add selectively, including to AstraZeneca and EssilorLuxottica. The portfolio ended the quarter with Healthcare still its largest sector overweight.

Financials contributed positively, led by Intercontinental Exchange and Mastercard. ICE rose more than 24% and was one of the Fund’s largest contributors, while Mastercard gained around 8%. The portfolio also benefited from Adyen. These holdings are deliberately different from traditional balance-sheet-intensive banks: they are predominantly high-return, asset-light financial infrastructure and payments franchises that fit our quality and sustainability criteria.

Industrials produced mixed absolute performance but positive stock selection relative to the benchmark. Kingspan rose more than 28%, supported by strong operating momentum and an accretive transaction that strengthens its position in data centres. RELX also contributed positively. These gains were partly offset by DSV, the largest individual detractor, which fell around 24%, as well as Equifax and Prysmian. We added to DSV during weakness and continued to manage Prysmian actively. The quarter again highlighted the breadth of structural growth represented within Industrials, from energy-efficient buildings and electrification to data and information services.

Consumer Discretionary was the principal weak area. Hermès and Home Depot both fell materially and together detracted almost 0.9 percentage points from performance, while InterContinental Hotels also declined. Consumer Staples were also soft, with Colgate-Palmolive the main detractor. Elsewhere, the portfolio’s lack of Energy exposure cost roughly half a percentage point of relative performance as the sector rallied sharply. Communication Services also detracted, with Alphabet falling modestly while the broader sector rose. Portfolio activity throughout the quarter remained disciplined: we recycled capital from recent winners into companies where valuation support had improved, while keeping overall equity exposure below the benchmark for much of the period.

Outlook & positioning

Looking ahead, we expect global developed equity markets to remain shaped by the tension between resilient corporate earnings and a more challenging inflation and interest-rate environment. The September rate increases by both the Fed and ECB underline that monetary policy cannot yet provide an uncomplicated tailwind to equity valuations. Higher energy prices and elevated long-term yields may continue to create volatility, particularly for highly valued or economically sensitive companies.

At the same time, the dispersion within markets continues to create attractive opportunities for fundamental stock pickers. AI remains a powerful long-term investment theme, but we believe the market is increasingly distinguishing between companies with credible earnings and cash-flow benefits and those supported primarily by narrative. Our exposure therefore remains focused on high-quality platforms and infrastructure beneficiaries such as Nvidia and Microsoft, while position sizes are actively managed as valuations and expectations evolve.

Healthcare remains a significant area of conviction. The sector contains a wide range of durable growth franchises across pharmaceuticals, biotechnology, medical technology and life-science tools, and recent volatility has allowed us to add selectively to businesses where we believe long-term earnings power is underappreciated. We also continue to find attractive opportunities in industrial companies benefiting from electrification, energy efficiency, automation and data-centre investment, as well as asset-light financial infrastructure businesses.

1Source: Carmignac, Bloomberg, data as of 30/09/2026. Performance of the A EUR Acc share class ISIN code: LU1966631001. Past performance is no guarantee of future results. The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged. They are net of fees (excluding any entry fees applied by the distributor).
2Reference indicator: MSCI WORLD (USD, net dividends reinvested).

Carmignac Portfolio Grandchildren

An intergenerational Fund focused on quality, sustainable companies
Discover the fund page

Carmignac Portfolio Grandchildren A EUR Acc

ISIN: LU1966631001
Recommended minimum investment horizon
5 years
Risk indicator*
4/7
SFDR - Fund Classification**
Article 9

*Risk Scale from the KID (Key Information Document). Risk 1 does not mean a risk-free investment. This indicator may change over time. **Sustainable Finance Disclosure Regulation (SFDR) 2019/2088. The SFDR classification of the Funds may change over time.

Main risks of the fund

Equity: The Fund may be affected by stock price variations, the scale of which is dependent on external factors, stock trading volumes or market capitalization.
Currency: Currency risk is linked to exposure to a currency other than the Fund’s valuation currency, either through direct investment or the use of forward financial instruments.
Discretionary Management: Anticipations of financial market changes made by the Management Company have a direct effect on the Fund's performance, which depends on the stocks selected.
The Fund presents a risk of loss of capital. Please refer to the Fund’s prospectus to view the exhaustive list of risks.

Fees

ISIN: LU1966631001
Entry costs
4.00% of the amount you pay in when entering this investment. This is the most you will be charged. Carmignac Gestion doesn't charge any entry fee. The person selling you the product will inform you of the actual charge.
Exit costs
We do not charge an exit fee for this product.
Management fees and other administrative or operating costs
1.71% of the value of your investment per year. This estimate is based on actual costs over the past year.
Performance fees
20.00% when the share class overperforms the Reference indicator during the performance period. It will be payable also in case the share class has overperformed the reference indicator but had a negative performance. Underperformance is clawed back for 5 years. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years, or since the product creation if it is less than 5 years.
Transaction Cost
0.30% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the investments underlying the product. The actual amount varies depending on the quantity we buy and sell.

Performance

ISIN: LU1966631001
Carmignac Portfolio Grandchildren+0.2−5.1+21.9+23.0−24.2+28.4+20.3+15.5
Reference Indicator+15.6+6.8+26.6+19.6−12.8+31.1+6.3+15.5
Carmignac Portfolio Grandchildren+7.1%+3.4%+9.4%
Reference Indicator+18.6%+12.3%+14.0%

Source: Carmignac at 30 Sep 2026.
Date of 1st NAV : 31/05/2019.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The Fund presents a risk of loss of capital.
The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Reference Indicator: MSCI World NR index

Share

Marketing communication. Please refer to the KID/KIID, prospectus of the fund before making any final investment decisions. This document is intended for professional clients.

This material may not be reproduced, in whole or in part, without prior authorisation from the Management Company. This material does not constitute a subscription offer, nor does it constitute investment advice. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. This material has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any securities or interests referred to herein or for any other purposes. The information contained in this material may be partial information and may be modified without prior notice. They are expressed as of the date of writing and are derived from proprietary and non-proprietary sources deemed by Carmignac to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by Carmignac, its officers, employees or agents.

Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.

Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Access to the Funds may be subject to restrictions regarding certain persons or countries. This material is not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the material or availability of this material is prohibited. Persons in respect of whom such prohibitions apply must not access this material. Taxation depends on the situation of the individual. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA.
The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital.

The Funds’ prospectus, KIDs, NAVs and annual reports are available at www.carmignac.com/en, or upon request to the Management Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The French investment funds (fonds communs de placement or FCP) are common funds in contractual form conforming to the UCITS or AIFM Directive under French law.

  • In the United Kingdom: the Funds’ respective prospectuses, KIIDs and annual reports are available at www.carmignac.com/en-gb, or upon request to the Management Company, or for the French Funds, at the offices of the acilities Agent, Carmignac UK Ltd, 2 Carlton House Terrace, London, SW1Y 5AF. This document was prepared by Carmignac Gestion, Carmignac Gestion Luxembourg or Carmignac UK Ltd. FP Carmignac ICVC (the “Company”) is an Investment Company with variable capital incorporated in England and Wales under registered number 839620 and is authorised by the FCA with effect from 4 April 2019 and launched on 15 May 2019. FundRock Partners Limited is the Authorised Corporate Director (the “ACD”) of the Company and is authorised and regulated by the FCA. Registered Office: Hamilton Centre, Rodney Way, Chelmsford, Essex, CM1 3BY, UK; Registered in England and Wales with number 4162989. Carmignac Gestion Luxembourg SA has been appointed as the Investment Manager and distributor in respect of the Company. Carmignac UK Ltd (Registered in England and Wales with number 14162894) has been appointed as a sub-Investment Manager of the Company and is authorised and regulated by the Financial Conduct Authority with FRN:984288.

  • In Switzerland: the prospectus, KIDs and annual report are available at www.carmignac.com/en-ch, or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon.

  • In Belgium: This document is intended for professional clients. This content has not been validated by FSMA. The decision to invest in the promoted fund should take into account all its characteristics or objectives as described in its prospectus. This communication is published by Carmignac Gestion S.A., a portfolio management company approved by the Autorité des Marchés Financiers (AMF) in France, and its Luxembourg subsidiary Carmignac Gestion Luxembourg, S.A., an investment fund management company approved by the Commission de Surveillance du Secteur Financier (CSSF). “Carmignac” is a registered trademark. “Investing in your Interest” is a slogan associated with the Carmignac trademark. This document does not constitute advice on any investment or arbitrage of transferable securities or any other asset management or investment product or service. The information and opinions contained in this document do not take into account investors’ specific individual circumstances and must never be interpreted as legal, tax or investment advice. The information contained in this document may be partial and could be changed without notice. This document may not be reproduced in whole or in part without prior authorisation. The risks and fees are described in the KID (Key Information Document). The prospectus, KID, the net asset-values and the latest (semi-) annual management report may be obtained, free of charge, in French or in Dutch, from the management company (tel. +352 46 70 60 1) or by consulting its website or www.fundinfo.com. These materials may also be obtained from Caceis Belgium S.A., the financial service provider in Belgium, at the following address: avenue du port, 86c b320, B-1000 Brussels. The Fund (fonds commun de placement or FCP) is a common fund in contractual form conforming to the UCITS Directive under French law. Access to the Fund may be subject to restrictions regarding certain persons or countries. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA. In case of subscription to a fund subject to Article 19bis of the Belgian Income Tax Code (CIR92), the investor will have to pay, upon redemption of his or her shares, a withholding tax of 30% on the income (in the form of interest, or capital gains or losses) derived from the return on assets invested in debt claims. Distributions are subject to withholding tax of 30% without income distinction. In case of subscription in a French investment fund (fonds commun de placement or FCP), you must declare on tax form, each year, the share of the dividends (and interest, if applicable) received by the Fund. Any complaint may be referred to complaints@carmignac.com or CARMIGNAC GESTION - Compliance and Internal Controls - 24 place Vendôme Paris France or on the website www.ombudsfin.be.

The Management Company can cease promotion in your country anytime. Investors have access to a summary of their rights at section 5 entitled "summary of investor rights" on the following links: UK ; Switzerland ; France ; Luxembourg ; Sweden. Belgium (French) ; Belgium (Dutch)

For Carmignac Portfolio Long-Short European Equities: Carmignac Gestion Luxembourg SA in its capacity as the Management Company for Carmignac Portfolio, has delegated the investment management of this Sub-Fund to White Creek Capital LLP (Registered in England and Wales with number OCC447169) from 2nd May 2024. White Creek Capital LLP is authorised and regulated by the Financial Conduct Authority with FRN : 998349.

Carmignac Private Evergreen refers to the Private Evergreen sub-fund of the SICAV Carmignac S.A. SICAV – PART II UCI, registered with the Luxembourg RCS under number B285278.